Opdivo (Nivolumab) for the Treatment of Unresectable or Metastatic Melanoma
Opdivo (nivolumab) is indicated for the treatment of unresectable or metastatic melanoma in...
Trending menu:
-
![]()
Humira for the Treatment of Hidradenitis Suppurativa
-
![]()
Lipaglyn (Saroglitazar) for Treating Hypertriglycerdemia in Type II Diabetes
-
![]()
Rozlytrek (entrectinib) for the Treatment of Solid Cancerous Tumours
-
![]()
Zynteglo for the Treatment of Transfusion-Dependent Beta-thalassemia
-
![]()
Piqray (alpelisib) for the Treatment of Advanced Breast Cancer
-
![]()
Polivy (polatuzumab vedotin) for the Treatment of Diffuse Large B-cell Lymphoma
Most Read
Latest Content
Signant Health launches partner programme to improve clinical trials
Zelboraf is indicated for the treatment of metastatic melanoma and Erdheim-Chester disease.
Opdivo (Nivolumab) for the Treatment of Unresectable or Metastatic Melanoma
Opdivo (nivolumab) is indicated for the treatment of unresectable or metastatic melanoma in patients with a positive BRAF V600 mutation who were previously treated and made progresssion with Yervoy (ipilimumab).
Soliris – Treatment for PNH, aHUS, gMG, and NMOSD
Soliris (eculizumab) is a drug indicated for the treatment of paroxysmal nocturnal haemoglobinuria (PNH), atypical haemolytic uremic syndrome (aHUS), generalised myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).
Humira for the Treatment of Hidradenitis Suppurativa
Humira (adalimumab) is a monoclonal antibody indicated for the treatment of more than ten indications, including rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa (HS), and uveitis.
June’s top news stories
AstraZeneca’s human monoclonal antibody Imfinzi (durvalumab) improved overall survival in the Phase III CASPIAN trial in first-line extensive-stage small cell lung cancer (SCLC).
Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia
Doptelet® (avatrombopag) is one of the first thrombopoietin (TPO) receptor agonists to be approved in the US for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD).
Lipaglyn (Saroglitazar) for Treating Hypertriglycerdemia in Type II Diabetes
Lipaglyn (Saroglitazar) is a dual peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of hypertriglyceridemia in Type II diabetics.
Rozlytrek (entrectinib) for the Treatment of Solid Cancerous Tumours
Rozlytrek (entrectinib) is a kinase inhibitor indicated for the treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive, advanced solid tumours in adult and paediatric patients.
Zynteglo for the Treatment of Transfusion-Dependent Beta-thalassemia
Zynteglo™ is a gene therapy indicated for the treatment of transfusion-dependent beta (β)-thalassemia (TDT) in patients aged 12 years and older.
Piqray (alpelisib) for the Treatment of Advanced Breast Cancer
Piqray® (alpelisib) is a kinase inhibitor indicated for the treatment of hormone receptor (HR) positive or HER2-negative advanced breast cancer with PIK3CA mutation in men and post-menopausal women.
Latest News
Close
Close
Close
Go Top
